- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04012814
Clinical Evaluation of a 1060 nm Diode Laser, PEMF and Vacuum Assisted MP RF for Non-invasive Fat Reduction
Clinical Evaluation of the Safety and Efficacy of a 1060 nm Diode Laser, Pulsed ElectroMagnetic Fields and Vacuum Assisted Multipolar Radio Frequency for Non-invasive Fat Reduction of the Abdomen and Flanks
Study Overview
Detailed Description
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
California
-
Los Altos, California, United States, 94022
- Berman Skin Institute
-
Sacramento, California, United States, 95816
- Laser & Skin Surgery Medical Group, Inc
-
Santa Monica, California, United States, 90404
- Batra Dermatology
-
-
Illinois
-
Chicago, Illinois, United States, 60026
- aFresh Medispa
-
-
Texas
-
Dallas, Texas, United States, 75390
- UT Southwestern Medical Center Department of Plastic Surgery
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
1. Able to read, understand and voluntarily provide written informed consent. 2. Healthy male or female, ≥ 18 years of age seeking treatment for unwanted fat in the flanks.
3. BMI score is less than 35. 4. Agree to not making any major changes in their diet or lifestyle during the course of the study.
5. Able and willing to comply with the treatment/follow-up schedule and requirements.
6. Women of child-bearing age are required to be using a reliable method of birth control at least 3 months prior to study enrollment and for the duration of the study, and have a negative Urine Pregnancy test at baseline.
Exclusion Criteria:
1. Pregnant in the last 3 months, intending to become pregnant, postpartum or nursing in the last 6 months.
2. Any previous liposuction/lipo-sculpture or any type of surgical procedure in the treatment area in the past 12 months.
3. History of immunosuppression/immune deficiency disorders (including AIDS and HIV infection) or use of immunosuppressive medications, 6 months prior to and during the course of the study.
4. History of hyperlipidemia, diabetes mellitus, hepatitis, blood coagulopathy or excessive bleeding.
5. Use of antiplatelet medications (81 mg acetylsalicylic acid daily permitted), anticoagulants, thrombolytics or anti-inflammatory medications within 2 weeks of treatment.
6. Having a history of skin cancer or any other cancer in the areas to be treated, including presence of malignant or pre-malignant pigmented lesions.
7. Having a permanent implant in the treatment area such as metal plates or an injected chemical substance such as silicone or parenteral gold therapy (gold sodium thiomalate).
8. Use of medications, herbs, food supplements, and vitamins known to induce photosensitivity to light exposure at the wavelength used or history of photosensitivity disorder.
9. Suffering from significant skin conditions in the treatment area or inflammatory skin conditions including but not limited to open lacerations, abrasions, herpes sores, cold sores, active infections.
10. Tattoos in the treatment area. 11. Poor skin quality (severe laxity). 12. Abdominal wall, muscular abnormality or hernia on physical examination. 13. Use of retinoids such as oral isotretinoin (Accutane™) within the past six months or during course of the study.
14. History of keloid or hypertrophic scar formation or poor wound healing in the treatment area.
15. As per the investigator's discretion, any physical or mental condition which may make it unsafe for the subject to participate.
16. Unable or unlikely to refrain from sun exposure, artificial tanning, including the use of tanning booths, prior to (six weeks) and during the course of the evaluation.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Subject treatment group
Treatment group receiving 3 diode treatments and 3 RF/PEMF treatments at Week 0, 8 and 16 with a follow-up at Week 24.
|
The FDA cleared device (Venus Bliss™) is a non-invasive medical aesthetic device designed for body contouring.
The device is comprised of a console, four 1060 nm diode laser applicators (60 mm x 60 mm).
A belt is included to allow the operator to secure the laser applicators on the lipolysis treatment area, allowing hands free operation.
The device uses vacuum assisted radiofrequency (RF) and PEMF (pulsed electromagnetic field) technology which has been shown in clinical studies to be safe and effective in body circumferential reduction and skin tightening.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in Aesthetic Appearance From Baseline
Time Frame: Week 24
|
Photographic evaluation by an independent, blinded reviewer with correct identification of pre-treatment baseline images when compared to post-treatment images taken at Week 24 using the Global Aesthetic Improvement Scale (GAIS).
A score of 0 is no change, 1 - slight change, 2 - moderate change, 3 - dramatic change.
An incorrect identification would result in a negative score (-1 for slight, -2 for moderate and -3 for dramatic change)
|
Week 24
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Subject Satisfaction: 5-Point Likert Subject Satisfaction Scale
Time Frame: Week 24
|
To assess subject satisfaction with treatment at the Week 24 visit using the 5-point Likert Subject Satisfaction Scale: 0 - very dissatisfied, 1 - dissatisfied, 2 - neutral, 3 - satisfied, 4 - very satisfied.
|
Week 24
|
Change in Fat Thickness
Time Frame: Week 24
|
Fat thickness was measured using ultrasound at one clinical site (14 subjects in total).
Change between Week 0 and Week 24 measurements is shown.
|
Week 24
|
Collaborators and Investigators
Sponsor
Investigators
- Study Director: Yoni Iger, PhD, Venus Concept LTD
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- BL0319
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Adipose Tissue Atrophy
-
Venus ConceptUniversity of TexasEnrolling by invitationAdipose Tissue AtrophyUnited States
-
Centre of Postgraduate Medical EducationUnknownAdipose Tissue Atrophy | Breast; Deformity, Congenital | Graft Loss | Breast; AtrophyPoland
-
Michael BezuhlyUnknownAdipose Tissue Atrophy | Graft Loss | Deformity of Reconstructed Breast
-
Institut National de la Santé Et de la Recherche...Unknown
-
Dominion Aesthetic Technologies, Inc.Completed
-
IR Technology, LLCCompletedObesity | Body Weight | Cellulite | Fat Burn | Abdominal Fat | Adipose Tissue AtrophyUnited States
-
Pennington Biomedical Research CenterRecruitingBrown Adipose TissueUnited States
-
BTL Industries Ltd.Completed
-
Clinical Nutrition Research Centre, SingaporeInstitute of Bioengineering and Bioimaging (IBB)Completed
Clinical Trials on Venus Bliss
-
Venus ConceptWithdrawn
-
Venus ConceptUniversity of TexasEnrolling by invitationAdipose Tissue AtrophyUnited States
-
Harvard UniversityHarvard Medical School (HMS and HSDM)CompletedDepression, AnxietyUnited States
-
Venus MedTech (HangZhou) Inc.UnknownAortic Valve Stenosis | Aortic Valve CalcificationChina
-
Venus ConceptCompletedVulvovaginal AtrophyItaly, Spain
-
Venus ConceptCompleted
-
Venus ConceptTerminatedAcne VulgarisUnited States
-
Venus ConceptTerminatedStriae DistensaeUnited States
-
University of MinnesotaRecruiting
-
University of MinnesotaCompletedAlopecia Areata | Lichen Planopilaris of ScalpUnited States